Redeye returns with an update following Paxman’s takeover offer to Dignitana and the directed share ...
Redeye initiates coverage of Momentum Group, a niche serial acquirer of high-quality industrial SMEs...
EMB Mission Bound (”EMB” eller ”Bolaget”), f.d. Embark Group, har publicerat bolagets delårsrapport ...
Obducat genomför en företrädesemission 20 mars - 3 april om 50 MSEK till teckningskurs 0,75 SEK, vil...
PW: Q1 EBIT below Q4 of SEK -28m Large negative effects from wood, FX and CTMP Higher wood costs and...
Pharma Equity Group (“PEG” or “the Company”) published its Year-End report for 2024 on the 20th of M...
Redeye comments on the positive phase I data from the study conducted by Leaderna in China.
Redeye comments on the clinical data from the SESAR study and the confusion it brought.
Redeye comments on the reverse split and new conditions of TO12.
This morning GomSpace announced a directed share issue of SEK200m to its largest shareholder the Har...
FDA's final minutes confirm that Orviglance is on track for NDA submission by mid-2025.
EBITA margin above 6% No more than 1.5x Net debt/EBITDA RTM Dividend at ~30% of net profit Ambitiou...
Redeye comments on Paxman’s takeover offer to Dignitana, valued at approximately SEK153m, representi...
Q4 figures slightly below ABGSCe Brage reserve uplift strengthens production outlook and valuation W...
Sprint Bioscience has secured 73.9% of a proposed SEK 31.
